In this study, it was noticed that blood RGS1 expression was elevated in NSCLC patients compared with HCs, which could be explained by the following: RGS1 was considered an oncogene that is mainly expressed in B lymphocytes, T lymphocytes and other immune cells in the tumour microenvironment (TME); meanwhile, the immune cells were abundant and infiltrated more in NSCLC patients, leading to high expression of RGS1.9 Here, RGS1 is linked to non-small cell lung carcinoma.